TNFRSF4 and melanoma: A recent study shows that Delta24-RGD therapy expressing the immunostimulatory OX40 ligand resulted in a cure of subcutaneous melanoma tumors and distant untreated tumors, including intracranial tumors, demonstrating that OVs can be successfully armed with co-signaling molecules to boost systemic antitumor immune responses.48